Tag
CHIP and pre-treatment neutropenia do not significantly affect survival or main toxicities in CAR-T therapy for hematologic cancers but may predict specific inflammatory toxicities, indicating distinct risk profiles for patient management.
A 64-year-old man with RET-altered medullary thyroid carcinoma who progressed on selpercatinib achieved complete response after modified dosing of tarlatamab with manageable CRS/ICANS.
This article explores a landmark mixed-methods study establishing a digital biomarker ontology for the early detection of Cytokine Release Syndrome (CRS). By identifying core physiological markers, researchers aim to transform immunotherapy
Clonal hematopoiesis (CH) occurs frequently in patients receiving CD19 or BCMA CAR T therapy and correlates with a higher risk of severe cytokine release syndrome (CRS), suggesting CH as a potential biomarker for CRS risk and a target for p
This phase II trial shows that combining glofitamab with R-CHOP or Pola-R-CHP is safe and effective as first-line treatment in younger patients with high-risk large B-cell lymphoma, achieving high durable response rates and manageable side
